Venture Partners

      • Christy Shaffer, PhD

        Venture Partner
        Managing Director of Hatteras Discovery

        Christy Shaffer, PhD

        Seasoned entrepreneur and biotech executive, Christy Shaffer, Ph.D. has over 20 years of experience in the life science industry. Following her career as a clinical scientist, international project leader and Associate Director of Pulmonary and Critical Care Medicine at Burroughs Wellcome Co., she joined Inspire Pharmaceuticals in 1995 as the first, full-time employee. She was responsible for raising over $300m for the company, including taking the company public in 2000. As President and CEO, Christy grew the company from 20 scientists to nearly 250 employees with revenues of over $100 million. Under her leadership, Inspire was named as “Best Place to Work for Scientists” by the Scientist magazine, and “Best Place to Work in North Carolina.” Christy retired from Inspire in March, 2010 and the company was acquired by Merck in 2011.

        Christy serves as the board chair of two Hatteras portfolio companies: G1 Therapeutics and Clearside Biomedical. Christy is a receptor pharmacologist by training, earning her Ph.D. in Pharmacology from the University of Tennessee Health Science Center in 1985. She received her post-doctoral training at The Chicago Medical School and the University of North Carolina at Chapel Hill.

        Community and Board Engagements:

        Christy played an integral role in the Chancellor’s Innovation Circle to enhance entrepreneurship and innovation across the UNC-Chapel Hill campus (2010 – 2012). She has served on numerous boards including the Council for Entrepreneurial Development, the NC Biotechnology Center, the Biotechnology Institute, BIO, PhRMA and Clinipace Worldwide. Christy received the Breath of Life Award for the Cystic Fibrosis Foundation in 2009 and the Hamner Leadership Award at the NC BIOTECH meeting in 2011.  TiE Atlanta awarded Christy the 2013 Venture Capital Entrepreneur Award at the TieCON Southeast conference.

        Christy also serves on multiple non-profit boards including the Board of Trustees for the Cystic Fibrosis Foundation (CFF), the CFF Therapeutics, Inc. board (chair), the NC School of Science and Mathematics Foundation board (former chair), the Morehead Planetarium and Science Center (chair). She is also a member of the Steering Committee for the NC state-wide science festival and the Frank Hawkin Keenan’s Institute’s advisory board.

      • Myla Lai-Goldman, MD

        Venture Partner

        Myla Lai-Goldman, MD

        Dr. Myla Lai-Goldman has over 20 years experience in the development, commercialization and adoption of novel molecular diagnostic assays. In 2011, with Drs. Chuck Perou and Neil Hayes of the University of North Carolina at Chapel Hill, she co-founded GeneCentric Diagnostics, a Hatteras Fund IV company, whose initial product, the Lung Subtype Platform (LSPTM) enables oncologists make more informed treatment decisions for their lung cancer patients.

        Until her retirement on December 31, 2008, Myla was Executive Vice President, Chief Medical Officer of Laboratory Corporation of America® Holdings (LabCorp®), where she managed LabCorp’s National Office of Quality and Science, through which she was responsible for all quality, science and medical activities for LabCorp and its subsidiaries. From 1998 until April 2008, Myla also served as Chief Scientific Officer of the company, where she was responsible for R & D. Until 2006, she managed the operations of the Company’s Center for Molecular Biology and Pathology in Research Triangle Park, NC; National Genetics Institute, Inc. in Los Angeles, CA; and ViroMed Laboratories, Inc. in Minneapolis, MN. Additionally, she held the position of Medical Director for the Center for Molecular Biology and Pathology from 1991 to 2005. Myla joined the Company in 1990.

        Myla earned an MD from the College of Physicians and Surgeons at Columbia University in New York, and completed postgraduate training in Internal Medicine at St Luke’s Hospital in New York, anatomic and clinical pathology at the UCLA Center for Health Sciences, and hematopathology at the University of North Carolina at Chapel Hill. She is board-certified in anatomic and clinical pathology.

        Community and Board Engagements:

        Myla serves on the Executive Committee of the Board of Directors for The Medical Foundation of North Carolina. Myla also serves on the Board of Directors of Sequenom.

      • Robert Morff, PhD

        Venture Partner

        Robert Morff, PhD

        Bob has deep experience in medical devices and diagnostics product and business development. Having already served as interim CEO of Pathfinder, he is now a director there. Bob also serves as a director at Histosonics. He was VP and CSO of the Wallace Coulter Foundation, Principal at Senmed Medical Ventures, and Senior Research Scientist in Eli Lilly’s Medical Device and Diagnostics Division. He has founded and led several companies in the microfluidics, stem cell, and tissue engineering areas.

        When Bob was with Eli Lilly’s Medical Devices and Diagnostics Division, he led the research teams that developed the first commercially available continuous glucose monitor and the first closed-loop drug delivery pump.

        Bob graduated from the University of Missouri with a B.S. and M.S. in electrical engineering, and a Ph.D. in medical physiology.

        Community and Board Engagements:

        Bob remains engaged with the Coulter Foundation, where he serves on the Oversight Committee for biomedical engineering grants. He is an advisor/mentor for the Kauffman Foundation’s PIPELINE entrepreneurs program, and also serves on review and advisory committees for a number of universities, including the University of Missouri, Duke University, the University of North Carolina, Vanderbilt University, MUSC, and the University of Miami.

      • Fred Goldwater

        Venture Partner

        Fred Goldwater

        Fred Goldwater provides strategic advisory services and executive support to companies serving the healthcare market. He has more than 30 years of executive management experience in manufacturing, financial services and healthcare and an extensive background in business development (including mergers, acquisitions, joint ventures and large-scale project development/implementation), operations, information systems, marketing and product development. Fred recently served as CEO of RealMed, a revenue cycle management company providing services to providers and payers.

        At the end of 2007, Fred retired from Blue Cross and Blue Shield of North Carolina. He had various responsibilities during his tenure including SVP of Strategic Development and CIO, SVP of Operations which included segment responsibilities for self insured, government and senior markets.

        Prior to Blue Cross and Blue Shield he was employed with Providian (formerly Capital Holding Corporation) and MeadWestvaco. Fred earned an MBA from Pace University in New York and an undergraduate degree from Babson College in Massachusetts.

        Community and Board Engagements:

        Fred currently serves as a strategic advisor to the NC Health Information Exchange and NC Community Care Network. He also serves as a consultant to American Well, Cain Brothers and Technosoft.

      • Dana Fowlkes, MD, PhD

        Venture Partner

        Dana Fowlkes, MD, PhD

        Dana is a general partner of HVP II and a venture partner with HVP III. He was co-founder and former CEO of Novalon, co-founder of Merlin and Cadus, and a former faculty member in the Deparment of Pathology at UNC.

 

 

      • June Almenoff, MD, PhD

        Executive-in-Residence

        June Almenoff, MD, PHD

        June S. Almenoff, M.D., Ph.D. most recently served as president, principal executive officer and chief medical officer of Furiex Pharmaceuticals, Inc. from its inception in 2010 through its acquisition by Forest/Actavis for up to $1.46 B in 2014.  She served as Furiex’s most senior executive officer, responsible for attaining all strategic and financial goals and was a member of the Board of Directors.  During her tenure, the company progressed a novel drug for diarrhea-predominant irritable bowel syndrome from Phase I through NDA filing.

        Dr. Almenoff joined Furiex after a successful 12-year career at GlaxoSmithKline (“GSK”). She was vice president in the clinical safety organization, where she served on the company’s senior governing medical boards and managed a diverse therapeutic portfolio supporting numerous regulatory approvals. Also during her tenure at GSK, she worked in the area of scientific licensing, leading the R&D diligence process for the acquisition of Stiefel Laboratories and establishing a licensing program for a drug development unit.   Dr. Almenoff led several GSK teams that developed pioneering systems for minimizing risk in early- and late-stage drug development; these have been widely implemented by pharmaceutical companies and regulatory agencies.  Their impact on the industry has been recognized by the Wall Street Journal Technology Innovation Award and several other prestigious awards. Dr. Almenoff also chaired a Pharma-FDA working group and was the lead author on its influential position paper.

        Prior to joining GSK, Dr. Almenoff was on the faculty of Duke University Medical Center, where she is currently a Consulting Professor of Medicine.  Dr. Almenoff earned a bachelor’s degree, cum laude, from Smith College. She graduated AWA from the M.D.-Ph.D. program at Mt. Sinai School of Medicine, and completed a residency in Internal Medicine and a fellowship in Infectious Diseases at Stanford University Medical Center. She is a Fellow of the American College of Physicians with 10 years of clinical practice experience and is an author on more than 50 publications.

        Community and Board Engagements:

        Dr. Almenoff serves on the Boards of Ohr Pharmaceutical (OHRP: Nasdaq) and the NC Council for Entrepreneurial Development.